High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition

Jinyang Cai; Sheeba Jacob; Richard Kurupi; Krista M. Dalton; Colin Coon; Patricia Greninger; Regina K. Egan; Giovanna T. Stein; Ellen Murchie; Joseph McClanaghan; Yuta Adachi; Kentaro Hirade; Mikhail Dozmorov; John Glod; Sosipatros A. Boikos; Hiromichi Ebi; Huaixiang Hao; Giordano Caponigro; Cyril H. Benes; Anthony C. Faber

Cell Reports (Jul 2022)

High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition

Jinyang Cai,
Sheeba Jacob,
Richard Kurupi,
Krista M. Dalton,
Colin Coon,
Patricia Greninger,
Regina K. Egan,
Giovanna T. Stein,
Ellen Murchie,
Joseph McClanaghan,
Yuta Adachi,
Kentaro Hirade,
Mikhail Dozmorov,
John Glod,
Sosipatros A. Boikos,
Hiromichi Ebi,
Huaixiang Hao,
Giordano Caponigro,
Cyril H. Benes,
Anthony C. Faber

Affiliations

Jinyang Cai: Philips Institute for Oral Health Research, School of Dentistry, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA
Sheeba Jacob: Philips Institute for Oral Health Research, School of Dentistry, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA
Richard Kurupi: Philips Institute for Oral Health Research, School of Dentistry, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA
Krista M. Dalton: Philips Institute for Oral Health Research, School of Dentistry, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA
Colin Coon: Philips Institute for Oral Health Research, School of Dentistry, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA
Patricia Greninger: Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA
Regina K. Egan: Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA
Giovanna T. Stein: Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA
Ellen Murchie: Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA
Joseph McClanaghan: Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA
Yuta Adachi: Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, Aichi 464-8681, Japan
Kentaro Hirade: Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, Aichi 464-8681, Japan
Mikhail Dozmorov: Department of Biostatistics, Virginia Commonwealth University, Richmond, VA 23298, USA
John Glod: National Cancer Institute, Pediatric Branch, Oncology, Bethesda, MD, USA
Sosipatros A. Boikos: Department of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA
Hiromichi Ebi: Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, Aichi 464-8681, Japan
Huaixiang Hao: Novartis Institute for Biological Research, 250 Massachusetts Avenue, Cambridge, MA 02139, USA
Giordano Caponigro: Novartis Institute for Biological Research, 250 Massachusetts Avenue, Cambridge, MA 02139, USA
Cyril H. Benes: Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA; Corresponding author
Anthony C. Faber: Philips Institute for Oral Health Research, School of Dentistry, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA; Corresponding author

Journal volume & issue: Vol. 40, no. 4
p. 111095

Abstract

Read online

Summary: Reoccurring/high-risk neuroblastoma (NB) tumors have the enrichment of non-RAS/RAF mutations along the mitogen-activated protein kinase (MAPK) signaling pathway, suggesting that activation of MEK/ERK is critical for their survival. However, based on preclinical data, MEK inhibitors are unlikely to be active in NB and have demonstrated dose-limiting toxicities that limit their use. Here, we explore an alternative way to target the MAPK pathway in high-risk NB. We find that NB models are among the most sensitive among over 900 tumor-derived cell lines to the allosteric SHP2 inhibitor SHP099. Sensitivity to SHP099 in NB is greater in models with loss or low expression of the RAS GTPase activation protein (GAP) neurofibromin 1 (NF1). Furthermore, NF1 is lower in advanced and relapsed NB and NF1 loss is enriched in high-risk NB tumors regardless of MYCN status. SHP2 inhibition consistently blocks tumor growth in high-risk NB mouse models, revealing a new drug target in relapsed NB.

CP: Cancer

Published in Cell Reports

ISSN: 2211-1247 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Science: Biology (General)
Website: http://www.cell.com/cell-reports/home

About the journal

Abstract

Keywords